Sars-cov-2 Mrna (tozinameran) Vaccine Side Effects
Medically reviewed by Drugs.com. Last updated on Apr 16, 2025.
Applies to sars-cov-2 mrna (tozinameran) vaccine: intramuscular suspension.
Local adverse events
- Very common (10% or more): Pain at injection site (78.3% to 90.5%), injection site swelling (up to 10.5%)
- Common (1% to 10%): Swelling, injection site redness/redness[Ref]
Nervous system
- Very common (10% or more): Headache (43.5% to 75.5%)
- Uncommon (0.1% to 1%): Lethargy
- Rare (0.01% to 0.1%): Bell's palsy
- Postmarketing reports: Dizziness, syncope[Ref]
Bell's palsy occurred in 4 patients in the treatment group versus 2 patients in the placebo group. Onset of facial paralysis occurred on day 37 after dose 1 (patient only received one dose), and days 3, 9, and 48 after dose 2 in the treatment group; onset of facial paralysis was day 30 and 102 in the placebo group. Currently available information is insufficient to determine a causal relationship with the vaccine.[Ref]
Other
- Very common (10% or more): Fatigue (49.4 to 77.5%), use of antipyretic or pain medication (27.8% to 45.2%), fever of 38C or higher (4.1% to 24.3%)
- Uncommon (0.1% to 1%): Malaise, asthenia[Ref]
Musculoskeletal
- Very common (10% or more): Chills (16.5% to 49.2%), new or worsened muscle pain (22.9% to 42.2%), new or worsened joint pain (11.8% to 24.3%)
- Postmarketing reports: Pain in extremity (arm)[Ref]
Gastrointestinal
- Very common (10% or more): Diarrhea (up to 11.7%)
- Common (1% to 10%): Nausea, vomiting
- Uncommon (0.1% to 1%): Decreased appetite[Ref]
Hypersensitivity
- Postmarketing reports: Severe allergic reactions including anaphylaxis, other hypersensitivity reactions (e.g., rash, pruritus, urticaria, angioedema)[Ref]
Cardiovascular
- Postmarketing reports: Pericarditis, myocarditis[Ref]
Dermatologic
- Uncommon (0.1% to 1%): Hyperhidrosis, night sweats[Ref]
Hematologic
- Uncommon (0.1% to 1%): Lymphadenopathy[Ref]
Metabolic
- Uncommon (0.1% to 1%): Decreased appetite[Ref]
References
1. "Product Information. Pfizer-BioNTech COVID-19 Vaccine PF (SARS-CoV-2 (COVID-19) mRNA BNT-162b2 vaccine)." Pfizer Inc., Madison, NJ.
2. (2022) "Product Information. Pfizer-BioNTech COVID-19 Vaccine PF (SARS-CoV-2 mRNA (tozinameran) vaccine)." Pfizer Inc.
Frequently asked questions
More about sars-cov-2 mrna (tozinameran) vaccine
Further information
Sars-cov-2 mrna (tozinameran) vaccine side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.